IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

IOVANCE BIOTHERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$14.21+0.59 (+4.33%)

Close on Oct 19, 2026

Market cap: $6.40M
P/E (TTM): –
Dividend yield: –

IOVANCE BIOTHERAPEUTICS, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Cash & Equivalents	163	122	115	238	84	73	19	82	145	107	34	45	20	0	0.51	1.29	0.01	0.00	–
Short-Term Investments	134	208	165	240	426	562	293	386	–	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	297	330	280	478	510	635	313	386	0	167	104	45	20	0	0.51	1.29	0.01	0.00	–
Receivables	82	69	0.15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Inventory	52	52	10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	12	12	17	7.27	3.55	6.66	9.41	6.85	3.92	3.04	0.28	0.07	0.17	0.01	0.01	0.00	–	–	–
Total Current Assets	443	457	308	479	508	636	316	475	149	170	104	45	20	0.01	0.52	1.30	–	–	–
Property, Plant & Equipment	131	109	114	105	101	59	8.54	2.68	2.45	2.37	1.68	1.53	0.03	0.02	0.03	0	–	–	–
Gross Property, Plant & Equipment	180	145	142	122	110	65	13	6.64	5.48	4.46	2.78	1.64	0.04	–	–	–	–	–	–
Accumulated Depreciation	-49	-36	-28	-17	-8.69	-5.58	-4.50	-3.96	-3.03	-2.08	-1.10	-0.10	-0.02	-0.01	0.00	0	–	–	–
Long-Term Investments	–	–	–	–	92	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	46	55	63	73	69	55	11	10	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	279	282	229	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	8.17	0.37	0.27	0.19	1.78	13	3.48	2.76	3.63	0	–	–	–	–	–	–	–	–	–
Total Assets	913	910	780	664	777	768	345	481	155	172	106	47	20	0.03	0.57	1.46	–	–	–
Accounts Payable	22	28	33	27	27	14	16	2.74	1.23	0.86	0.96	1.25	0.41	1.10	0.19	0.03	–	–	–
Accrued Expenses	111	82	69	52	57	35	16	12	8.36	4.11	0.67	0.33	1.52	–	–	–	–	–	–
Current Portion of Leases	4.04	13	7.78	13	5.06	6.28	7.25	4.90	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	138	122	110	91	89	55	39	14	9.60	4.97	1.63	1.66	2.27	11	13	0.82	–	–	–
Long-Term Debt	–	1.00	1.00	1.00	1.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	44	44	67	72	65	45	4.25	5.80	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	48	57	75	84	71	52	12	11	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	32	32	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	12	2.35	0.23	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	215	200	196	164	156	112	46	15	9.89	4.97	1.63	1.66	2.27	11	13	0.82	–	–	–
Total Debt	–	1.00	1.00	1.00	1.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Preferred Stock	–	–	–	–	–	–	–	–	–	–	0	0	0.00	–	–	–	–	–	–
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–
Additional Paid-In Capital	3,458	3,096	2,594	2,069	1,795	1,487	869	839	395	324	208	121	82	19	15	2.32	–	–	–
Retained Earnings	-2,776	-2,385	-2,012	-1,568	-1,172	-830	-571	0.30	-249	-157	-104	-77	-65	-31	-27	-1.68	–	–	–
Comprehensive Income & Other	16	-1.05	2.53	-0.90	-0.60	0.02	0.22	-0.04	0	0.03	0.05	0	–	–	–	–	–	–	–
Shareholders' Equity	699	710	585	500	622	656	299	466	145	167	104	45	18	-11	-13	0.64	-0.01	0.00	0.06
Total Equity	699	710	585	500	622	656	299	466	145	167	104	45	18	-11	-13	0.64	-0.01	0.00	0.06
Total Liabilities & Equity	913	910	780	664	777	768	345	481	155	172	106	47	20	0.03	0.57	1.46	–	–	–
Shares Outstanding(shares)	412	305	256	188	157	148	126	123	73	62	49	34	20	0.82	0.78	0.74	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 48.4%
Operating margin: -92.7%
Net margin: -89.1%
Return on equity, FY2025: -55.5%

Financial strength

Current ratio: 4.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 103.7%

Valuation

P/E ratio: –
Price to sales: 0.02
Price to book: 0.01
Dividend yield: –